FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OMB APPROVAL OMB Number: 3235

	OMB Number:	3235-0287					
	Estimated average burden						
1	hours per response.	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SEIDENBERG BETH C					2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC					[(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
					BCRX]						2	Directo	r		10% Ow	ner
					-							Officer below)	Officer (give title		Other (s below)	pecify
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)						below)			below)		
2190 PARKWAY LAKE DRIVE					05/13/2010											
(Street)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)					
BIRMINGHAM AL 35244-										X Form filed by One Reporting Person						
(City) (State) (Zip)			_								Form filed by More than One Reporting Person				ting	
(- 9)																
		Tal	ble I - Non-D	erivativ	/e Se	curitie	s Ac	quired, Di	sposed o	f, or Ber	neficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Di					Execution Date,				3. 4. Securities Acquired (A) Transaction Code (Instr. 5) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)			5. Amour Securitie Beneficia	s For		n: Direct	7. Nature of Indirect Beneficial
						(Month/Day/Year)		r) 8) `			Owned Following Reported		(I) (Instr. 4)	str. 4) (Ownership (Instr. 4)	
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			
			Table II - Der (e.g					uired, Disp s, options,				Owned				
1. Title of Derivative Security	2. Conversion or Exercise		3A. Deemed Execution Date, if any	ate, Transac Code (Ir		nsaction of		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and An of Securities Underlying			ies g	8. Price of Derivative Security	9. Number of derivative Securities		10. Ownership Form:	11. Nature of Indirect Beneficial
(Instr. 3)	Price of Derivative Security		(Month/Day/Year							Derivative (Instr. 3 a		(Instr. 5)	Beneficially Owned Following Reported Transaction((Instr. 4)		Direct (D) or Indirect (I) (Instr. 4)	
									1		Amount	1				
											or Number					
				Codo	v	(A)	(D)	Date	Expiration	Title	of					
.	<u> </u>	+		Code	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	(4)	(D)	Exercisable	Date	Title	Shares					
Non- Qualified Stock Option ⁽¹⁾	\$7.01	05/13/2010		A		15,000		06/14/2010 ⁽²⁾	05/13/2020	Common Stock	15,000	\$0	15,000	0	D	

Explanation of Responses:

- 1. Automatic non-employee director grant
- 2. The option vests 1/12 per month for 12 months, beginning on June 14, 2010.

/s/ Michael Richardson, by power of attorney

05/17/2010

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.